Docteur RENAUD FELTEN

Thèses universitaires

• Identification de nouvelles cibles thérapeutiques au cours du syndrome de Gougerot-Sjögren primitif (SJp)

  2023

  Identification of new therapeutic targets in primary Sjögren's syndrome (pSS)

  Immunologie🎓 Strasbourg

  Direction : Jacques-Éric Gottenberg

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys

  2026

  ArticleJoint Bone Spine

• Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture

  2025

  ArticleBMC Medical Education

• Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica

  2025

  ArticleArthritis & rheumatology

• When generative artificial intelligence answers to Google Trends about spondyloarthritis: what does a French expert panel think about it?

  2025

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

• Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop

  2024

  ArticleJoint Bone Spine

• Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

  2024

  ArticleRheumatology

• Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease

  2024

  ArticleRMD Open

• The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials

  2024

  ArticleAutoimmunity Reviews

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Livres & ouvrages

• 📕

  Description, prévalence et facteurs de risque de l'ostéonécrose aseptique chez les patients transplantés du rein

  2016 · 288 p.

Source : Google Books — filtre catégories médicales/santé/sciences.

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• HOPITAL DE HAUTEPIERRE

  1 Avenue MOLIERE, 67200 Strasbourg

  ☎ 0388116768Hospitalier🏥 Voir cet établissement
  113 m113 m192 m

  © OpenStreetMap · Photos Wikimedia Commons (CC)

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Vidéos & interventions (1)

Source YouTube · recherche par nom (homonymes possibles).

• 3:29

  💉 Dr. Renaud Felten, l'expert médical de Sim&Care, simulateur de ponction lombaire

  InSimo · 586 vues

Top publications · les plus citées

• 1

  Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial

  JAMA · 2022

  📚 81 citations🎯 RCR 7.51Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ImportanceFew treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica.ObjectiveTo compare the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica.Design, Setting, and ParticipantsThis double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017 to October 2019. Final follow-up occurred in November 2020. Inclusion criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive protein level [CRP PMR-AS] >10) and prednisone dose greater than or equal to 10 mg per day.InterventionsPatients were randomly assigned to receive intravenous tocilizumab (8 mg/kg; n = 51) or placebo (n = 50) every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone.Main Outcomes and MeasuresThe primary efficacy end point was CRP PMR-AS less than 10 (range, 0-100; higher values indicate greater activity; no minimal clinically important difference defined) combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 included in this report, including disease activity (measured by CRP PMR-AS) and the proportion of patients no longer taking prednisone.ResultsOf the 101 randomized patients (mean age, 67.2 years; 68 [67.3%] women), 100 (99%) received at least 1 infusion and 100 completed the trial. The primary end point was achieved in 67.3% of patients in the tocilizumab group and 31.4% of patients in the placebo group (adjusted difference, 36.0% [95% CI, 19.4%-52.6%]; adjusted relative risk, 2.3 [95% CI, 1.5-3.6]; P < .001). Of 11 reported secondary end points at 24 weeks, 7 showed significant differences favoring tocilizumab, including mean CRP PMR-AS score (7.5 [95% CI, 5.4-9.6] vs 14.9 [95% CI, 11.4-18.4]; adjusted difference, −7.5 [95% CI, −11.2 to −3.8]; P < .001) and the percentage of patients no longer receiving prednisone (49.0% vs 19.6%; adjusted difference, 29.3% [95% CI, 18.9%-39.7%]; adjusted relative risk, 2.5 [95% CI, 1.8-3.5]; P < .001). The most frequent adverse events were infections, experienced by 23 patients (46.9%) in the tocilizumab group and 20 (39.2%) in the placebo group.Conclusions and RelevanceAmong patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with a CRP PMR-AS less than 10 with reduced prednisone requirements at week 24. Further research is needed to confirm efficacy and to determine the balance of potential benefits and harms.Trial RegistrationClinicalTrials.gov Identifier: NCT02908217

• 2

  Variability of Primary Sjögren's Syndrome Is Driven by Interferon-α and Interferon-α Blood Levels Are Associated With the Class II HLA-DQ Locus

  Arthritis & rheumatology (Hoboken, N.J.) · 2022

  📚 42 citations🎯 RCR 3.82Top 12% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  ObjectivePrimary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptomic, proteomic, cellular, and genetic data with clinical phenotypes in a cohort of 351 patients with primary SS.MethodsWe analyzed blood transcriptomes and genotypes of 351 patients with primary SS who were participants in a multicenter prospective clinical cohort. We replicated the transcriptome analysis in 3 independent cohorts (n = 462 patients). We determined circulating interferon‐α (IFNα) and IFNγ protein concentrations using digital single molecular arrays (Simoa).ResultsTranscriptome analysis of the prospective cohort showed a strong IFN gene signature in more than half of the patients; this finding was replicated in the 3 independent cohorts. Because gene expression analysis did not discriminate between type I IFN and type II IFN, we used Simoa to demonstrate that the IFN transcriptomic signature was driven by circulating IFNα and not by IFNγ protein levels. IFNα protein levels, detectable in 75% of patients, were significantly associated with clinical and immunologic features of primary SS disease activity at enrollment and with increased frequency of systemic complications over the 5‐year follow‐up. Genetic analysis revealed a significant association between IFNα protein levels, a major histocompatibility (MHC) class II haplotype, and anti‐SSA antibody. Additional cellular analysis revealed that an MHC class II HLA–DQ locus acts through up‐regulation of HLA class II molecules on conventional dendritic cells.ConclusionWe identified the predominance of IFNα as a driver of primary SS variability, with IFNα demonstrating an association with HLA gene polymorphisms.

• 3

  New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review

  Joint bone spine · 2023

  📚 40 citations🎯 RCR 4.99Top 8% NIH

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France

  Collection2021figshare

  Abstract Background The risk of severe COVID-19 and its determinants remain largely unknown in patients with autoimmune and inflammatory rheumatic diseases. The objective of this study was to assess the prevalence of COV

• Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France

  Collection2021figshare

  Abstract Background The risk of severe COVID-19 and its determinants remain largely unknown in patients with autoimmune and inflammatory rheumatic diseases. The objective of this study was to assess the prevalence of COV

• Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage

  Collection2020SAGE Journals

  Aims:With the arrival of conventional synthetic (csDMARDs), biological (bDMARDS) and then targeted synthetic (tsDMARDs) disease-modifying anti-rheumatic drugs, the therapeutic arsenal against rheumatoid arthritis (RA) ha

• Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection

  Audiovisual2021Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the <b>authors</b>. For a full list of declarations, including funding and author disclosure statements, please see the full text

• Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis

  Collection2020SAGE Journals

  Background:Pathogenic inflammatory pathways are largely shared between different autoimmune and inflammatory diseases (AIDs). This offers the potential to develop a given targeted therapy in several AIDs.Methods:We analy

• Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey

  Collection2021SAGE Journals

  Background:Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empir

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche